Functional Polymorphism of Cyclooxygenase-2 Gene (G–765C) in Depressive PatientsGałecki P.a · Florkowski A.a · Bieńkiewicz M.b · Szemraj J.c
Departments of aAdult Psychiatry, bQuality Control and Radiological Protection and cMedical Biochemistry, Medical University of Lodz, Lodz, Poland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Depressive disorder (DD) is characterized by an inflammatory process and oxidative stress. Cyclooxygenase-2 (COX-2), the expression of which increases in depression, is an enzyme involved in inflammation and free radical processes. The aim of our study was to assess the correlation between single nucleotide polymorphism G–765C of the COX-2 gene and recurrent DD. Methods: The study was carried out in a group of 181 patients treated for recurrent DD, and in 149 healthy subjects of the control group (CG). Polymerase chain reaction/restriction fragment length polymorphism was used for genotyping. Results: A statistically significant difference in genotype distribution was observed as a result of the comparison between the CG and the patients with DD. We demonstrated that the presence of the –765G allele in the COX-2 gene increased 2.1-fold the risk of DD development, whereas the presence of a homozygote (G–765G) in the analyzed gene increased the risk of DD development 2.5-fold. Conclusion: According to the obtained results, it may be proposed with some caution that the presence of both the –765G allele and the G–765G genotype in the COX-2 gene may confer a susceptibility to an increased risk of recurrent DD in the Polish population.
© 2010 S. Karger AG, Basel
- López-Muñoz F, Alamo C: Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009;15:1563–1586.
- Hashimoto K: Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105–123.
- Swaab DF, Bao AM, Lucassen PJ: The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005;4:141–194.
- Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B, Cardinali DP: Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138–151.
- Monkul ES, Malhi GS, Soares JC: Mood disorders: review of structural MRI studies. Acta Neuropsychiatr 2003;15:368–380.
Gałecki P, Śigielski J, Florkowski A, Bobińska K, Pietras T, Szemraj J: Analysis of two polymorphisms of the manganese superoxide dismutase gene: Ile-58Thr and Ala-9Val in patients with recurrent depressive disorder. Psychiatry Res, in press.
- Tzvetkov MV, Brockmöller J, Roots I, Kirchheiner J: Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 2008;18:495–506.
- Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M: The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27–53.
- Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res 2007;32:1749–1756.
- Müller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007;12:988–1000.
- Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F: Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009;612:54–60.
- Jun TY, Pae CU, Hoon-Han S, Chae JH, Bahk WM, Kim KS, Serretti A: Possible association between –G308A tumor necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003;13:179–181.
- Pae CU, Yu HS, Kim TS, Lee CU, Lee SJ, Jun TY, Lee C, Serretti A, Paik IH: Monocyte chemoattractant protein-1 (MCP1) promoter –2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004;127:279–281.
- Traks T, Koido K, Eller T, Maron E, Kingo K, Vasar V, Vasar E, Kõks S: Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder. BMC Med Genet 2008;9:111.
- Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–1073.
- Ma SL, Tang NL, Zhang YP, Ji LD, Tam CW, Lui VW, Chiu HF, Lam LC: Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer’s disease in Chinese. Neurobiol Aging 2008;29:856–860.
- Minghetti L: Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004;63:901–910.
- Kuehl FA Jr, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 1980;210:978–984.
- Vesce S, Rossi D, Brambilla L, Volterra A: Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 2007;82:57–71.
- Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310–1315.
- Madrigal JL, Moro MA, Lizasoain I, Lorenzo P, Fernández AP, Rodrigo J, Boscá L, Leza JC: Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 2003;28:1579–1588.
- Cassano P, Hidalgo A, Burgos V, Adris S, Argibay P: Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenomics J 2006;6:381–387.
- Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo-controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680–684.
- Müller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M: COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin Investig Drugs 2004;13:1033–1044.
- Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, Mullan M: The cyclooxygenase 2 –765C promoter allele is a protective factor for Alzheimer’s disease. Neurosci Lett 2006;395:240–243.
- Tay A, Squire JA, Goldberg H, Skorecki K: Assignment of the human prostaglandin-endoperoxide synthase 2 (PTGS2) gene to 1q25 by fluorescence in situ hybridization. Genomics 1994;23:718–719.
- Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD: A familial Alzheimer’s disease locus on chromosome 1. Science 1995;269:970–973.
- Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631–1636.
World Health Organization: ICD 10: International Statistical Classification of Diseases and Related Health Problems, rev 10. Geneva, WHO, 1992.
- Bland JM, Altman DG: Statistics notes: the odds ratio. BMJ 2000;320:1468.
- Madrigal JL, García-Bueno B, Caso JR, Pérez-Nievas BG, Leza JC: Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets 2006;5:561–568.
- Leonard BE: The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:767–780.
- Casolini P, Catalani A, Zuena AR, Angelucci L: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002;68:337–343.
- Müller N, Riedel M, Schwarz MJ: Psychotropic effects of COX-2 inhibitors: a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004;37:266–269.
- Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201–217.
- Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E: The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression – and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007;28:826–831.
- McNally L, Bhagwagar Z, Hannestad J: Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008;13:501–510.
- Müller N, Schwarz MJ: COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008;14:1452–1465.
- Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A, Identification of New Elements of Plaque Stability (INES) Study Group: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221–2228.
- Lee HC, Lin HC, Tsai SY: Severely depressed young patients have over five times increased risk for stroke: a 5-year follow-up study. Biol Psychiatry 2008;64:912–915.
- Sullivan PF: Spurious genetic associations. Biol Psychiatry 2007;61:1121–1126.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.